ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internat…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
This week | ||
ADMA Biologics (ADMA) Faces Class Actions And Probes Over Revenue Allegations Multiple securities class action lawsuits have been filed against ADMA Biologics (NasdaqGM:ADMA) following allegations of channel stuffing and misleading revenue recognition. Regulatory and internal investigations are underway into the company’s revenue practices, internal controls, and undisclosed related party transactions. The volume and scope of these legal actions introduce material questions around ADMA Biologics’ financial reporting and governance practices. ADMA Biologics operates... | ||
ADMA Biologics (ADMA) Stock Looks Undervalued Even After A 5 Year Run ADMA Biologics stock has delivered a very large 5 year return while its broader valuation checks still point to the shares looking inexpensive on several metrics, which puts the recent share price at US$8.87 under the spotlight. Over 5 years, ADMA Biologics has returned roughly 4.6x an initial investment, which puts current pricing in a very different context compared to where long term holders started. For the business to keep supporting this valuation, investors will be watching whether... | ||
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights Adma Biologics (ADMA) closed the most recent trading day at $8.97, moving 1.21% from the previous trading session. | ||
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock? | ||
Older | ||